Cancer-focused Agensys Inc. nailed down its second big pharma deal of the month, licensing its Phase I monoclonal antibody for prostate stem cell antigen (PSCA) to Merck & Co. Inc. for $17.5 million up front and as much as $11.5 million more over the next year, depending on milestones. (BioWorld Today) Read More
